BridgeBio Pharma, Inc.
BBIO
Clasificación en acciones
#1620
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Precio por acción
$68.06
Capitalización bursátil
$13.31B
Cambio (1 día)
2.52%
Cambio (1 año)
23.93%
País
US
Comercio BridgeBio Pharma, Inc. (BBIO)
Categoría
Healthcare
Ganancias de BridgeBio Pharma, Inc. (BBIO)
Ganancias en Jun 2026 TTM: $-706.17M
Secondo gli ultimi rapporti finanziari di BridgeBio Pharma, Inc., gli utili attuali della società sono $-706.17M. Nel 2023, la società ha registrato un utile di $-653.25M, una disminución en comparación con agli utili del 2022, che erano di $-484.65M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de BridgeBio Pharma, Inc. desde 2017 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-706.17M | 30.24% |
| 2024 | $-542.19M | -17.00% |
| 2023 | $-653.25M | 34.79% |
| 2022 | $-484.65M | -17.36% |
| 2021 | $-586.45M | 16.02% |
| 2020 | $-505.49M | 75.16% |
| 2019 | $-288.59M | 70.31% |
| 2018 | $-169.45M | 286.59% |
| 2017 | $-43.83M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -846.98% |
US
|
|
| $-3.09B | 337.15% |
US
|
|
| $-4.02B | 468.73% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -376.23% |
NL
|
